Acceleron Pharma Inc (XLRN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Habib J. Dable
Employees:
173
128 SIDNEY STREET, CAMBRIDGE, MA 02139
617-649-9200

Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 10.583 Billion Shares Outstanding60.901 Million Avg 30-day Volume 2.014 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 189.99 / 99.98 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from XLRN instead.

View recent insider trading info

Funds Holding XLRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XLRN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

43.1 Thousand total shares from 8 transactions

Exercise Derivative Conversion (M)

41.7 Thousand total shares from 9 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KANGO SUJAY EVP, CHIEF COMMERCIAL OFFICER

  • Officer
43,509 2021-09-27 7

MCLAUGHLIN KEVIN F SVP, CFO AND TREASURER

  • Officer
92,919 2021-09-23 5

VENESS ADAM M SVP, GENERAL COUNSEL AND SEC.

  • Officer
18,923 2021-09-21 5

DABLE HABIB J CEO AND PRESIDENT

  • Officer
  • Director
739,086 2021-07-01 3

MCCOURT THOMAS A

  • Director
6,044 2021-04-19 2

ZAKRZEWSKI JOSEPH S

  • Director
34,499 2021-04-05 3

SMITH KAREN L.

  • Director
19,457 2021-04-05 3

KEARNEY TERRENCE C

  • Director
6,749 2021-01-29 1

NADER FRANCOIS

  • Director
6,749 2021-01-29 1

HAMILL LAURA

  • Director
474 2021-01-29 1

BACKSTROM JAY T. EVP, RESEARCH AND DEVELOPMENT

  • Officer
20,781 2021-01-29 2

MALIK KEMAL

  • Director
1,622 2021-01-29 1

HITE CHRISTOPHER

  • Director
930 2021-01-29 1

CELGENE CORP /DE/

BRISTOL MYERS SQUIBB CO

  • 10% Owner
No longer subject to file 2020-07-09 0

GEORGE JEAN

  • Director
5,127 2020-01-22 0

QUISEL JOHN D EVP, CHIEF BUSINESS OFFICER

  • Officer
53,316 2020-01-02 0

BRISTOL MYERS SQUIBB CO

  • 10% Owner
6,971,772 2019-11-20 0

KUMAR RAVINDRA SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
86,986 2019-09-10 0

POPS RICHARD F

  • Director
32,500 2019-01-25 0

MANIATIS TOM

  • Director
136,731 2019-01-25 0

ZELDIN ROBERT K EVP & CHIEF MEDICAL OFFICER

  • Officer
19,103 2019-01-25 0

CELGENE CORP /DE/

6,824,685 2019-01-18 0

SHERMAN MATTHEW L EVP & CHIEF MEDICAL OFFICER

  • Officer
77,267 2018-04-03 0

ROVALDI CHRISTOPHER SVP, PROGRAM MGMT AND OPS

  • Officer
25,858 2018-04-03 0

MCGUIRE TERRANCE

  • Director
1,250 2017-03-02 0

ERTEL STEVEN D EVP & CHIEF OPERATING OFFICER

  • Officer
136,977 2017-03-02 0

KNOPF JOHN L CEO AND PRESIDENT

  • Officer
  • Director
214,084 2016-11-09 0

KANIA EDWIN M JR

  • Director
0 2015-01-08 0

MCGUIRE TERRANCE

POLARIS VENTURE MANAGEMENT CO IV LLC

POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP

POLARIS VENTURE PARTNERS IV LP

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
2,621,738 2014-06-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2021-09-27 19:21:31 -0400 2021-09-27 M 5,000 d 25,000 direct yes

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2021-09-27 19:21:31 -0400 2021-09-27 S 5,000 $175.00 d 18,509 direct yes -4.0595 -3.0911 0.0 1 -5.8431 3

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2021-09-27 19:21:31 -0400 2021-09-27 M 5,000 $40.61 a 23,509 direct yes -4.0595 -3.0911 0.0 1 -5.8431 3

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-24 M 170 d 20,500 direct yes

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-24 M 170 $41.64 a 16,051 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-24 M 5,200 d 11,262 direct yes

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-24 M 5,200 $40.61 a 15,881 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-24 S 5,370 $160.38 d 10,681 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 M 9,800 d 16,462 direct yes

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 S 18,647 $160.26 d 11,664 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 M 2,500 $30.17 a 13,181 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 M 2,500 d 2,663 direct yes

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 M 7,330 $41.64 a 30,311 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 M 7,330 d 20,670 direct yes

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 S 983 $161.26 d 10,681 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

MCLAUGHLIN KEVIN F - Officer SVP, CFO AND TREASURER

2021-09-24 19:36:42 -0400 2021-09-23 M 9,800 $40.61 a 22,981 direct yes 2.1859 -2.3425 2.1859 2 -3.7849 4

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-22 18:08:28 -0400 2021-09-21 S 6,650 $150.05 d 18,923 direct yes 4.8861 7.6702 14.3519 4 0.0 1

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2021-09-22 17:56:44 -0400 2021-09-21 M 5,000 d 30,000 direct yes

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-22 18:08:28 -0400 2021-09-21 M 1,450 d 0 direct yes

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-22 18:08:28 -0400 2021-09-21 M 1,450 $41.20 a 25,573 direct yes 4.8861 7.6702 14.3519 4 0.0 1

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2021-09-22 17:56:44 -0400 2021-09-21 S 5,000 $150.03 d 18,509 direct yes 4.8861 7.6702 14.3519 4 0.0 1

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-22 18:08:28 -0400 2021-09-21 M 5,200 d 0 direct yes

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-22 18:08:28 -0400 2021-09-21 M 5,200 $30.17 a 24,123 direct yes 4.8861 7.6702 14.3519 4 0.0 1

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2021-09-22 17:56:44 -0400 2021-09-21 M 5,000 $40.61 a 23,509 direct yes 4.8861 7.6702 14.3519 4 0.0 1

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-09 17:07:38 -0400 2021-09-09 S 1,407 $130.00 d 18,923 direct yes 0.1133 3.9039 31.3524 38.0201 13 -0.1812 3

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-09 17:07:38 -0400 2021-09-08 S 6 $130.00 d 20,330 direct yes 0.1133 3.9039 31.3524 38.0201 13 -0.1812 3

VENESS ADAM M - Officer SVP, GENERAL COUNSEL AND SEC.

2021-09-09 17:07:38 -0400 2021-09-07 F 587 $129.36 d 20,336 direct 0.1133 3.9039 31.3524 38.0201 13 -0.1812 3

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ACCELERON PHARMA INC XLRN 2021-10-26 22:15:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 21:45:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 21:15:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 20:45:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 20:15:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 19:45:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 19:15:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 18:45:03 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 18:15:03 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 17:45:03 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 17:15:03 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 16:45:04 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 16:15:03 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 15:45:03 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 15:15:03 UTC -0.186 0.256 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 14:45:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 14:15:05 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 13:45:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 13:15:03 UTC -0.18 0.25 1300000
ACCELERON PHARMA INC XLRN 2021-10-26 12:45:03 UTC -0.18 0.25 1300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Defensive Long Fund XLRN -6.0 shares, $-539.22 2020-03-31 N-PORT
FundVantage Trust- Gotham Master Neutral Fund XLRN -28.0 shares, $-3150.84 2020-09-30 N-PORT
JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund XLRN -2546.0 shares, $-345263.06 2021-03-31 N-PORT
Trust for Professional Managers- Convergence Long/Short Equity Fund XLRN -379.0 shares, $-49607.31 2021-05-31 N-PORT
Nuveen Investment Trust- Nuveen Equity Market Neutral Fund XLRN -1500.0 shares, $-196335.0 2021-05-31 N-PORT
Nuveen Investment Trust II- Nuveen Equity Long/Short Fund XLRN -3800.0 shares, $-497382.0 2021-05-31 N-PORT
TIFF INVESTMENT PROGRAM- TIFF Multi-Asset Fund XLRN -1273.0 shares, $-159748.77 2021-06-30 N-PORT
FundVantage Trust- Gotham Hedged Plus Fund XLRN -788.0 shares, $-98886.12 2021-06-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund XLRN -100.0 shares, $-12549.0 2021-06-30 N-PORT
AQR Funds- AQR Alternative Risk Premia Fund XLRN -357.0 shares, $-44799.93 2021-06-30 N-PORT
First Trust Exchange-Traded Fund III- First Trust Long/Short Equity ETF XLRN -1846.0 shares, $-230860.76 2021-07-31 N-PORT

Elevate your investments